✦ LIBER ✦

A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: A gynecologic oncology group study

✍ Scribed by W.T. Creasman; G.A. Omura; M.F. Brady; E. Yordan; P.J. DiSaia; J. Beecham

Book ID: 118890705
Publisher: Elsevier Science
Year: 1991
Tongue: English
Weight: 138 KB
Volume: 36
Category: Article
ISSN: 0020-7292
DOI: 10.1016/0020-7292(91)90782-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized trial of cyclophosphamide,

A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: A Gynecologic Oncology Group Study

✍ William T. Creasman; George A. Omura; Mark F. Brady; Edgardo Yordan; Philip J. D 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 488 KB

A randomized trial of cyclophosphamide a

A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study

✍ George Omura; John A. Blessing; Clarence E. Ehrlich; Alexander Miller; Edgardo Y 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 593 KB

Adjuvant chemotherapy with fluorouracil,

Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer a prospective randomized trial

✍ Aman U. Buzdar; George R. Blumenschein; Terry L. Smith; Kimberly C. Powell; Gabr 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 532 KB

Between May 1977 and April 1980, 238 patients with operable breast cancer were treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy. All patients were randomized to receive FAC alone or FAC with nonspecific immunotherapy with Bacillus Calmette-Guerin (BCG) vaccine

Randomized phase III trial of chemoimmun

Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stages III and IV suboptimal disease ovarian cancer: A Southwest Oncology Group study

✍ David S. Alberts; Nancy Mason-Liddil; Robert V. O'Toole; Thomas M. Abbott; Richa 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 763 KB

Analysis of patient age as an independen

Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin–cyclophosphamide versus carboplatin–cyclophosphamide in stages III (suboptimal) and IV ovarian cancer: A southwest oncology group study

✍ David S. Alberts; Steve Dahlberg; Stephanie J. Green; Dava Garcia; Edward V. Han 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 888 KB

Randomized Study Comparing Carboplatin/C

Randomized Study Comparing Carboplatin/Cyclophosphamide and Cisplatin/Cyclophosphamide as First-Line Treatment in Patients with Stage III/IV Epithelial Ovarian Cancer and Small Volume Disease

✍ H.G. Meerpohl; W. Sauerbrei; H. Kühnle; M. Schumacher; A. Pfleiderer 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 109 KB